Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.63 |
| ▸ | ESRRG | P62508 | 16/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.54 |
| ▸ | ESRRB | O95718 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7519361 | 1.00 | ESR1 (0.63) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL5725990 | 1.00 | ESR1 (0.63) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL7108560 | 1.00 | ESR1 (0.63) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL8367727 | 0.97 | ESR1 (0.60) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL8367728 | 0.97 | ESR1 (0.60) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL8362758 | 0.96 | ESR1 (0.58) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL8362756 | 0.96 | ESR1 (0.58) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL8368223 | 0.96 | ESR1 (0.58) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL5726815 | 0.94 | ESRRG (0.57) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL5727016 | 0.94 | ESRRG (0.57) | ESR1ESR2ESRRGCYP19A1ESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016110805-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
| EP-1056701-B1 | E-2- 4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORP (FI) | 2003-10-22 | — | — | EP | disclosed |
| US-6395785-B1 | ANTICHOLESTEROL AGENTS; HORMONE REPLACEMENT THERAPY | ORION CORPORATION (FI) | 2002-05-28 | — | — | US | disclosed |
| EP-0900077-B1 | Use of a toremifene metabolite for lowering serum cholesterol level. | ORION CORP (FI) | 2002-02-06 | — | — | EP | disclosed |
| EP-1056701-A1 | E-2- 4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORPORATION (FI) | 2000-12-06 | — | — | EP | disclosed |
| US-6037379-A | Serum cholesterol lowering agent | ORION CORPORATION (FI) | 2000-03-14 | — | — | US | disclosed |
| WO-1999042427-A1 | E-2-[4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORPORATION (FI) | 1999-08-26 | — | — | WO | disclosed |
| EP-0779808-B1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ORION YHTYMAE OY (FI) | 1999-08-18 | — | — | EP | disclosed |
| US-5912273-A | COMPOUNDS WITH CHLORO AND HYDROXY GROUPS FOR OSTEOPOROSIS | ORION-YHTYMA OY (FI) | 1999-06-15 | — | — | US | disclosed |
| EP-0900077-A1 | SERUM CHOLESTEROL LOWERING AGENT | ORION-YHTYMÄ OY (FI) | 1999-03-10 | — | — | EP | disclosed |
| US-5750576-A | BONE DISORDERS | ORION-YHTYMA OY (FI) | 1998-05-12 | — | — | US | disclosed |
| WO-1997032574-A1 | SERUM CHOLESTEROL LOWERING AGENT | Orion-Yhtymä Oy (FI) | 1997-09-12 | — | — | WO | disclosed |
| EP-0779808-A1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ORION-YHTYMÄ OY (FI) | 1997-06-25 | — | — | EP | disclosed |
| WO-1996007402-A1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | Orion-Yhtymä Oy (FI) | 1996-03-14 | — | — | WO | disclosed |